权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Crosslinked Nanosponges for the Topical Treatment of Wound Biofilms

用于局部治疗伤口生物膜的交联纳米海绵

基本信息

批准号：
10189492
负责人：
Robin Patel
金额：
$ 38.77万
依托单位：
UNIVERSITY OF MASSACHUSETTS AMHERST
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-24 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10189492
关键词：
Anti-Bacterial Agents Antibiotic Therapy Antibiotics Antimicrobial Resistance Bacteria Bacterial Antibiotic Resistance Bacterial Infections Bypass Cells Coculture Techniques Development Disease Dose Emulsions Engineering Evaluation Excision Exhibits Fibroblasts Formulation Generations Goals Immune response In Vitro Infection Inflammation Laboratories Mammalian Cell Methods Microbial Biofilms Microcapsules drug delivery system Modeling Multi-Drug Resistance Mus Nature Oils Operative Surgical Procedures Pathogenicity Phytochemical Polymers Property Pseudomonas aeruginosa Refractory Research Resistance Resistance Process Siderophores Solubility Staphylococcus aureus Structure System Testing Therapeutic Tissues Topical application Toxic effect Volatile Oils Wound Infection Wound models antimicrobial antimicrobial drug aqueous bacterial resistance bactericide base biomaterial compatibility cell growth chronic infection cost crosslink cytokine dose information healing in vivo in vivo evaluation inhibitor/antagonist interest methicillin resistant Staphylococcus aureus microbicide nanomaterials nanomedicine non-healing wounds pre-clinical prevent quorum sensing self assembly systemic inflammatory response therapeutic evaluation wound biofilm wound healing wound treatment

项目摘要

Project Summary/Abstract Crosslinked Nanosponges for the Topical Treatment of Wound Biofilms The goal of the proposed research is the creation of therapeutics against multidrug-resistant biofilm infections. These infections are very difficult to treat: The refractory nature of biofilm infections make them highly resistant to standard antibiotics, a situation exacerbated by the development of antibiotic-resistant bacteria. In our research we will synergistically integrate the nanomedicine capabilities of Rotello with biofilm expertise of Patel. In preliminary research Rotello has developed crosslinked nanosponges imbibed with essential oil antimicrobials that penetrate and kill biofilm-based bacteria with minimal effect on host cells. Patel has created effective wound biofilm models that allow efficient assessment of therapeutics. In our proposed research we will develop new nanosponge therapeutics and test them against biofilms in vitro, in co-culture with mammalian cells, and finally in vivo. Aim 1: Rotello will fabricate and characterize polymeric nanosponges and optimize their activity against multi-drug resistant biofilms including S. aureus (MRSA) biofilm models. These nanosponges will be tested against mammalian cells in co-culture models, with the goal of maximizing antibacterial efficacy and minimizing mammalian cell toxicity. Aim 2: Rotello will screen therapeutics including antibiotics, quorum sensing inhibitors, and siderophores to create Generation 2 combination antibacterial agents. Aim 3: Patel will perform dosing and pre-clinical mouse studies of the optimized Generation 1 and 2 formulations, determining wound healing activity. Rotello will screen for inflammation.

项目总结/文摘